Osteoporosis osteitis deformans also known as Paget's disease of bone, is a condition that causes enlarged and weakened bones. The cause of paget’s disease is still unknown and can occur in the any bone of the body such as the spine, leg bones, skull, and pelvis and can lead to fracture, arthritis in joints and bone pain. Pressure on nerves, headache, hearing loss, increased head size, hip pain, are some of the symptoms observed in the patients with paget’s disease. The disease can be diagnosed by alkaline phosphatase blood test and bone scans. The treatment of paget’s disease of bone comprises but is not limited to osteoporosis drugs such as Alendronate, Pamidronate and Zoledronic acid.
Some of the companies having a pipeline of osteoporosis osteitis deformans include Novartis AG, Dexa Medica Group, Bayer AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.